Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Switzerland
/
Pharmaceuticals & Biotech
/
Newron Pharmaceuticals
NWRN
Newron Pharmaceuticals
Newron Pharmaceuticals (NWRN) – Binary CNS Bets with 3-to-1 Upside
HE
HedgeY
Not Invested
Community Contributor
Published
08 Jul 25
Updated
08 Jul 25
8
Set Fair Value
2
votes
Share
HedgeY
's Fair Value
CHF 17.00
54.5% undervalued
intrinsic discount
08 Jul
CHF 7.74
Loading
1Y
8.9%
7D
13.3%
Author's Valuation
CHF 17.0
54.5% undervalued
intrinsic discount
HedgeY's Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
HedgeY
's
Fair Value
CHF 17.0
54.5% undervalued
intrinsic discount
Future estimation in
5 Years
time period
Past
Future
-25m
209m
2014
2017
2020
2023
2025
2026
2029
2030
Revenue €209.3m
Earnings €64.5m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
32.02%
Pharma revenue growth rate
1.01%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.42%
Calculation
€64.53m
Earnings '30
x
9.58x
PE Ratio '30
=
€618.00m
Market Cap '30
€618.00m
Market Cap '30
/
25.14m
No. shares '30
=
€24.58
Share Price '30
€24.58
Share Price '30
Discounted to 2025 @ 6.23% p.a.
=
€18.17
Fair Value '25
€18.17
Fair Value '25
Converted to CHF @ 0.9354 EUR/CHF Exchange Rate
=
CHF 17.00
Fair Value '25
